Jillion Therapeutics Inc.
Publicly observedBrooklyn, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Brooklyn | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Jillion Therapeutics Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | KNVYBLASYW88 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Jul 2025Publicly observed
NIH SBIR/STTR award: Identification of therapeutic molecules to treat amphetamine use disorders using our DNA-encoded library (DEL) technology
USD 398,093.00 · National Institute on Drug Abuse · Source: NIH RePORTER (opens in a new tab)
- Grant15 May 2025Publicly observed
NIH SBIR/STTR award: Synergy between Artificial Intelligence and DNA-Encoded Library technologies to Identify Polypharmacological Therapeutics for Substance Use Disorders
USD 399,483.00 · National Institute on Drug Abuse · Source: NIH RePORTER (opens in a new tab)
- Grant1 Sept 2024Publicly observed
NIH SBIR/STTR award: Advancing DEL-derived Small Molecule Inhibitors of Pathological Tau Toward Preclinical Development for Alzheimer’s Disease and Tauopathies
USD 1,118,025.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.